Ionut-Gabriel Funingana

7PUBLICATIONS
68CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Nov 28, 2024
Coordinated protein modules define DNA damage responses to carboplatin at single cell resolution in human ovarian carcinoma models.

Jacob S Bedia, Ying-Wen Huang, Antonio Delgado Gonzalez

|Jul 25, 2023
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial.

James Spicer, Bristi Basu, Ana Montes

|Jul 20, 2023
The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.

Philip Smith, Thomas Bradley, Lena Morrill Gavarró

|Jan 12, 2023
Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors.

Ionut-Gabriel Funingana, Jacob S Bedia, Ying-Wen Huang

|Oct 26, 2022
Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer.

Filipe Correia Martins, Dominique-Laurent Couturier, Ines de Santiago

|Aug 19, 2022
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer.

Susana Banerjee, Vasiliki Michalarea, Joo Ern Ang

Pageof 2

Frequent Collaborators

5 joint publications

James D Brenton

3 joint publications

Carolin Margarethe Sauer

3 joint publications

Matthew Eldridge

3 joint publications

Iain McNeish